Abstract:Thrombosis is a leading cause of death worldwide [1]. Recombinant tissue-type plasminogen activator (tPA) is the FDA-approved thrombolytic drug for ischemic strokes, myocardial infarction and pulmonary embolism. tPA is a multi-domain serine protease of the trypsin-family [2] and catalyses the critical step in fibrinolysis [3], converting the zymogen plasminogen to the active serine protease plasmin, which degrades the fibrin network of thrombi and blood clots. tPA is rapidly inactivated by endogenous plasminogen activators inhibitor-1 (PAI-1) [4] (Fig. 1). Engineering on tPA to reduce its inhibition by PAI-1 without compromising its thrombolytic effect is a continuous effort [5]. Tenecteplase (TNK-tPA) is a newer generation of tPA variant showing slower inhibition by PAI-1 [6]. Extensive studies to understand the molecular interactions between tPA and PAI-1 have been carried out [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], however, the precise details at atomic resolution remain unknown. We report the crystal structure of tPA·PAI-1 complex here. The methods required to achieve these data include: (1) recombinant expression and purification of a PAI-1 variant (14-1B) containing four mutations (N150H, K154T, Q319L, and M354I), and a tPA serine protease domain (tPA-SPD) variant with three mutations (C122A, N173Q, and S195A, in the chymotrypsin numbering) [19]; (2) formation of a tPA-SPD·PAI-1 Michaëlis complex in vitro [19]; and (3) solving the three-dimensional structure for this complex by X-ray crystallography [deposited in the PDB database as 5BRR]. The data explain the specificity of PAI-1 for tPA and uPA [19], [20], and provide structural basis to design newer generation of PAI-1-resistant tPA variants as thrombolytic agents [19].

Design, Synthesis, and Sar of Embelin Analogues As the Inhibitors of Pai-1 (plasminogen Activator Inhibitor-1)

Structural Insight into Inactivation of Plasminogen Activator Inhibitor-1 by A Small-Molecule Antagonist

Synthesis and Biological Evaluation of Menthol-Based Derivatives As Inhibitors of Plasminogen Activator Inhibitor-1 (PAI-1)

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Characterization of A Small Molecule Pai-1 Inhibitor, Zk4044

Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition

Inhibition of PAI-1: a new anti-thrombotic approach.

[Synthesis and AchE Inhibitory Activity of 2-Phenoxy-indan-1-one Derivatives].

Crystal Structure of Pai-1 in Complex with Gallate

Plasminogen activator inhibitor-1 inhibitors: a patent review (2006 – present)

The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo

Design and Synthesis of Benzo-Spirocyclic Derivatives as Potent PARP-1 Inhibitors

A Specific Plasminogen Activator Inhibitor-1 Antagonist Derived from Inactivated Urokinase

Design, Synthesis and Biological Evaluation of Novel Trimethylpyrazine-2-carbonyloxy-cinnamic Acids As Potent Cardiovascular Agents

Design, Synthesis and Biological Evaluation of Novel Molecules As Potent PARP-1 Inhibitors.

Piericones A and B As Potent Antithrombotics: Nanomolar Noncompetitive Protein Disulfide Isomerase Inhibitors with an Unexpected Chemical Architecture.

Structural Basis of Specific Inhibition of Tissue-Type Plasminogen Activator by Plasminogen Activators Inhibitor-1

Probing nanosecond motions of plasminogen activator inhibitor-1 by time-resolved fluorescence anisotropy.

[Design, Synthesis and Biological Evaluation of Novel Diaryl Ethers Bearing a Pyrimidine Motif As Human Pin1 Inhibitors].

Design, Synthesis and Antithrombotic Evaluation of Novel Non-Peptide Thrombin Inhibitors.